. Author manuscript; available in PMC: 2023 Dec 1.

Published in final edited form as: Clin Nutr. 2022 Oct 4;41(12):2607–2613. doi: 10.1016/j.clnu.2022.09.016

Table 2.

Hazard Ratios (With 95% CIs) of Adipose Tissue Radiodensity and Mortality among Patients with Breast Cancer

	Overall Mortality
Radiodensity	Model 1^a	Model 2^b
SAT Radiodensity, HU
Low	1.22 (0.95–1.56)	1.23 (0.95–1.58)
Middle	1.00	1.00
High	1.50 (1.21–1.86)	1.45 (1.15–1.81)
VAT Radiodensity, HU
Low	1.06 (0.85–1.31)	1.06 (0.85–1.32)
Middle	1.00	1.00
High	1.24 (0.99–1.55)	1.16 (0.90–1.50)
	BC-Specific Mortality
Radiodensity	Model 1^a	Model 2^b
SAT Radiodensity, HU
Low	1.09 (0.78–1.53)	1.09 (0.77–1.53)
Middle	1.00	1.00
High	1.29 (0.94–1.76)	1.32 (0.95–1.84)
VAT Radiodensity, HU
Low	1.02 (0.75–1.38)	1.02 (0.75–1.39)
Middle	1.00	1.00
High	1.14 (0.84–1.56)	1.16 (0.82–1.64)

Abbreviations: BC-Specific, breast-cancer-specific; CI, confidence interval; HU, Hounsfield Unit; SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue.

Model 1 included the following covariates: age at diagnosis, race and ethnicity (Non-Hispanic White, Black, Hispanic, Asian/Pacific Island, Others), smoking (never, former, current), Charlson comorbidity index (0, 1–2, 3+), stage (I, II, III), ER (ER+, ER−), PR (PR+, PR−), and HER2 (HER2+, HER2−, unknown).

Model 2: Model 1 + BMI at CT scan (<18.5, 18.5–24.9, 25–29.9, ≥30 kg/m²).